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We evaluated the usefulness of preoperative 18F-ﬂuorodeoxyglucose positron emission tomography/
computed tomography (18F-FDG PET/CT) examinations to predict the pathological features in primary 
breast cancer.  In particular,  we evaluated the correlation between the maximum standardized uptake 
values (SUVmax) obtained by 18F-FDG PET/CT and the Ki67 expression in estrogen receptor (ER)-
positive invasive ductal carcinoma (IDC).  Primary IDC patients operated between March 2009 and 
July 2013 at Okayama University Hospital were enrolled.  We evaluated the correlations between the 
SUVmax and age,  postoperative pT,  histological grade,  lymph vascular invasion,  status of hormone 
receptor,  human epidermal growth factor receptor 2 (HER2),  Ki67 expression and node status.  The 
Ki67 expression was classiﬁed as high (＞14ｵ) versus low (ｦ14ｵ).  We enrolled 138 patients with IDC.  
Their median SUVmax was 3.85 (range: 0-52.57).  In a univariate analysis,  the SUVmax was signiﬁ-
cantly related to age,  pT,  histological grade,  lymphovascular invasion,  hormone receptor status,  
HER2 status,  node status and Ki67.  In the 113 patients with ER-positive IDC,  there was a signiﬁcant 
correlation between Ki67 and SUVmax (p＝0.0030).  The preoperative 18F-FDG PET/CT results of IDC 
patients had signiﬁcant relationships with pathological status parameters.  The determination of the 
preoperative SUVmax might help classify Luminal A and Luminal B patients among luminal-type 
breast cancer patients.
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ne of the main characteristics of malignant 
tumors is the acceleration of glycolysis.  
18F-ﬂuorodeoxyglucose positron emission tomography/
computed tomography (18F-FDG PET/CT) is an imag-
ing modality that can be used to visualize the local 
existence of a lesion by reﬂecting the increased 
metabolism of cancer cells [1].  PET/CT has been 
used for the diagnosis,  staging,  and detection of 
metastases and recurrence,  and it has recently come 
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to be used to estimate the response to chemotherapy 
early in malignancies,  including breast cancer.  
Several research groups have also suggested that the 
uptake of FDG to the primary tumor can be used to 
predict the prognoses of breast cancer patients [2-5].
　 The breast cancer subtype classiﬁed according to 
positivity for estrogen receptor (ER)/progesterone 
receptor (PgR) and human epidermal growth factor 
receptor 2 (HER2) is regarded as a predictive factor 
for the need for adjuvant therapy.  We have also begun 
using this subtype classiﬁcation in our decision-making 
process regarding the need for adjuvant chemother-
apy,  along with the expression of the cellular marker 
Ki67 as an indicator of the proliferation of cancer 
cells.  However,  the method for measuring the Ki67 
index is not currently standardized among institutions,  
and the cut-oﬀ value for Ki67 also varies among insti-
tutions [6].  In addition,  in breast cancer cases of the 
luminal type,  the level of Ki67 can be used as a 
parameter to distinguish Luminal B from Luminal A 
breast cancer.  The diﬀerentiation of Luminal A and 
Luminal B is very important to the judgment of the 
necessity of chemotherapy and the use of neoadjuvant 
chemotherapy [6].  It is somewhat diﬃcult to measure 
the exact level of Ki67 before surgery,  and it could be 
very helpful if we could replace the measurement of 
Ki67 with PET/CT.
　 Several studies examined the correlation of 18F-
FDG uptake and clinicopathological features of breast 
cancer,  and in most of these studies the examination 
was carried out without making a distinction between 
invasive ductal carcinoma (IDC) and invasive lobular 
carcinoma (ILC).  However,  the morphologic charac-
teristics of ILCs are diﬀerent from those of IDCs 
[7],  and two-thirds of ILC patients were reported to 
show false-negative results in a PET/CT examination 
[8].
　 The goals of the present study were to determine 
whether: (1) 18F-FDG uptake is associated with bio-
logical parameters including Ki67 expression only for 
IDC,  and (2) the use of maximum standardized uptake 
(SUVmax) values could help diﬀerentiate Luminal A 
and Luminal B cases among luminal-type breast cancer 
patients.  We assessed the levels of 18F-FDG uptake to 
primary breast cancers using SUVmax values.
Materials and Methods
　 Patients. We studied 138 patients with IDC 
who underwent 18F-FDG PET/CT scans before sur-
gery and had not received neoadjuvant chemotherapy 
between March 2009 and July 2013 at the Okayama 
University Hospital.  Patients with blood glucose val-
ues of＞150mg/dl during PET/CT image acquisition 
were excluded.
　 18F-FDG PET/CT imaging. All patients 
underwent 18F-FDG PET/CT scans at the Okayama 
Diagnostic Imaging Center (Okayama,  Japan).  The 
patients fasted at least 5-6h before the 18F-FDG 
PET examination.  Each patientʼs blood glucose was 
measured before the tracer injection to ensure a level 
of 150mg/dl.  Ninety min after an intravenous (IV) 
administration of 3.7MBq/kg 18F-FDG,  a whole-body 
scan from the upper end of the orbit to the femoral 
region was performed with the patient in the supine 
position with elevation of both upper limbs.  Images 
were obtained using a PET/CT scanner (Biograph 
LSO/Sensation16,  Siemens,  Munchen,  Germany).  A 
transmission scan using CT for attenuation correction 
and anatomical imaging was acquired for 90s.  An IV 
contrast agent was not administered to patients for the 
CT portion of the 18F-FDG PET/CT.
　 A region of interest (ROI) was placed in the pri-
mary lesion,  including the highest uptake area (circu-
lar ROI,  3cm dia. ),  and the SUVmax in the ROI was 
calculated.  The SUV was calculated using the follow-
ing formula:
SUV＝activity in the ROI (MBq/ml)/injected dose 
(MBq/kg body weight).
　 Histological analysis. Tumor histology and 
biological parameters were evaluated using the breast 
cancer tissue obtained by surgery.  The histological 
type was assessed by hematoxylin and eosin staining,  
and the histological grade was determined using the 
Scarﬀ-Bloom-Richardson classiﬁcation.  ER and PgR 
were deﬁned as being positive when at least 10ｵ of 
the tumor cells showed positive immunohistochemistry 
(IHC) staining for these molecules.  The HER2 status 
was deﬁned as positive when more than 30ｵ of the 
cells showed a positive IHC result for this molecule.  
Ki67 expression was considered high when at least 
14ｵ of the cancer cells exhibited positive staining,  
according to the suggestion of the St.  Gallen interna-
tional expert consensus 2013 [6].
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　 Statistical analysis. A software package 
(JMP 9.0.2; SAS Institute,  Tokyo) was used for all 
statistical analyses.  The correlations between the 
SUVmax and other parameters evaluated in this study 
were calculated using the Mann-Whitney U-test (when 
2 categories were compared) and the Kruskal-Wallis 
test (when more than 2 categories were compared).  A 
receiver operator characteristic (ROC) curve was used 
to identify the potential SUVmax cut-oﬀ value predic-
tive of diﬀerent luminal subtypes.  An area under the 
curve (AUC) of 1.0 would indicate a perfect test,  
whereas 0.5 would represent a non-useful test.  All 
tests were two-sided,  and p-values＜0.05 were con-
sidered signiﬁcant.  All procedures were carried out 
with the adequate understanding and written consent 
of each patient.
Results
　 Patient characteristics. The median age of 
the 138 patients was 52 years (range 22-86 years).  
The median pT was 15mm (range 1-93mm),  and 96 
(69ｵ) patients were stage I.  ER was positive in 113 
(82ｵ) of the patients,  and PgR was positive in 95 
(69ｵ) patients.  Twenty (14ｵ) of the patients were 
HER2-positive,  and 13 (9ｵ) patients had a triple-
negative tumor (i.e.,  their tumor was negative for ER,  
PgR and HER2).  The median SUVmax was 3.85 
(range 0-52.57),  and FDG uptake to the breast cancer 
was not seen in 10 patients.
　 Association between median SUVmax and 
clinicopathological features. Table 1 shows the 
associations between SUVmax and the patientsʼ clini-
copathological features.  There were signiﬁcant cor-
relations between SUVmax and all of the clinico-
pathological features examined: age,  tumor size,  
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Table 1　 Association between SUVmax in the breast tumor and patient clinicopathological features
Variables n (%) median SUVmax (IQR) p value
Age ｦ49 54 (39) 5.0 (2.9-6.9) 0.026a
＞49 84 (61) 3.1 (2.1-6.4)
Tumor size (mm) ＜10 31 (22) 2.2 (1.2-3.5) ＜0.0001b
10 to 20 65 (47) 3.1 (2.5-5.5)
≧20 42 (30) 6.7 (5.2-11.7)
Lymph node status positive 46 (33) 5.1 (3.2-7.0) 0.004a
negative 92 (67) 3.1 (2.1-5.9)
Histological grade 1 53 (38) 2.8 (2.3-4.6) ＜0.0001b
2 37 (27) 3.2 (2.2-6.6)
3 48 (35) 5.7 (3.6-11.4)
Lymphovascular invasion 0 60 (43) 2.8 (2.0-5.4) 0.014b
1 46 (33) 4.1 (2.8-6.3)
2 17 (12) 6.0 (2.7-6.8)
3 15 (11) 5.9 (4.0-9.5)
ER positive 113 (82) 3.2 (2.3-5.5) ＜0.0001a
negative 25 (18) 8.7 (4.0-13.2)
PgR positive 95 (69) 3.1 (2.3-5.4) ＜0.0001a
negative 43 (31) 6.3 (3.2-10.7)
HER2 positive 20 (14) 5.5 (3.4-9.3) 0.039a
negative 116 (84) 3.5 (2.3-6.6)
unknown 2
Ki67 ＞14 71 (51) 5.5 (2.8-9.3) ＜0.0001a
ｦ14 67 (49) 2.9 (2.1-4.5)
subtype Luminal 113 (82) 3.1 (2.3-5.5) ＜0.0001b
HER2 12 (9) 7.4 (3.8-12.1)
Triple negative 13 (9) 8.8 (5.3-13.2)
IQR,  interquartile range; ER,  estrogen receptor; PgR,  progesterone receptor; HER2,  human epidermal growth factor receptor 2.
aMann-Whitney U-test.
bKruskal-Wallis test.
lymph node status,  histological grade,  lymphovascular 
invasion,  ER,  PgR,  HER2,  Ki67,  and subtype.
　 There was a signiﬁcant correlation between pT and 
SUVmax (p＜0.0001).  There were signiﬁcant associ-
ations between SUVmax and lymphovascular invasion 
(p＝0.012) and the lymph node status (p＝0.004).  
With regard to lymphovascular invasion,  the tumors 
with lymphovascular invasion had signiﬁcantly higher 
18F-FDG uptake (4.6 vs. 2.8; p＝0.008).
　 ER positivity was associated with signiﬁcantly 
lower median SUVmax (p＜0.0001),  and PgR positiv-
ity was similarly associated with signiﬁcantly lower 
median SUVmax (p＜0.0001).  The SUVmax was also 
signiﬁcantly inﬂuenced by HER2 positivity (p＝0.039).  
Patients who had more than 14ｵ Ki67 expression had 
signiﬁcantly higher 18F-FDG uptake (p＜0.0001).
　 With regard to the tumor histological grade,  there 
was a signiﬁcant correlation between the histological 
grade and SUVmax (p＜0.0001),  and the grade 3 tumor 
group had signiﬁcantly higher 18F-FDG uptake than the 
group with grade 1＋2 (5.7 vs. 2.9; p＜0.0001).  The 
tumor subtype had a signiﬁcant impact on the 18F-
FDG uptake to the primary tumor (p＜0.0001),  and 
the 13 patients with triple-negative tumors had sig-
niﬁcantly higher uptake compared to the 125 patients 
with non-triple negative tumors (8.8 vs. 3.3; p＝0.0007).
　 Among the patients with ER positivity,  there was 
a signiﬁcant correlation between Ki67 and SUVmax 
(p＝0.0030).  To investigate whether SUVmax could 
be used to help classify Luminal A and Luminal B 
cases among luminal-type tumors,  we used the 
SUVmax to create an ROC curve for Ki67.  The area 
under the ROC curve was 0.664,  and the cut-oﬀ 
SUVmax was 4.34 (Fig.  1).
Discussion
　 In this study,  we assessed the correlations between 
the tumor uptake of 18F-FDG and clinicopathological 
features in breast cancer patients who underwent 
curative surgery.  Since there are some biological and 
morphologic diﬀerentiations between IDC and ILC [7,  
8],  we enrolled only IDC patients in this study.  Our 
analyses revealed signiﬁcant associations between 
higher SUVmax values and younger age,  larger pT,  
lymph node metastases,  higher histological grade,  
lymphovascular invasion,  negative hormone receptor 
status,  HER2 expression,  higher Ki67 index and tri-
ple negativity in comparison with non-triple negativity.
　 Several reports indicated that high levels of 18F-
FDG uptake are correlated with larger tumor size 
[2-4,  9-11].  In agreement with those reports,  the 
present results showed that pT signiﬁcantly inﬂuences 
the SUVmax.  There was also a signiﬁcant diﬀerence 
between the SUVmax of the tumors＞20mm and the 
0-20-mm tumors (6.7 vs. 2.9; p＜0.0001),  indicating 
that the levels of SUVmax in tumors at more than T2 
are signiﬁcantly higher.
　 We observed positive correlations between the 18F-
FDG uptake and the hormone receptor status,  HER2 
expression,  and tumor grade.  This is consistent with 
previous reports about ER negativity [2-4,  9,  10,  
12,  13],  PgR negativity [2,  4,  12,  13],  HER2 
positivity [2-4,  9,  11] and tumor grade [2-4,  
9-14].
　 In agreement with earlier studies [9,  10,  14,  
15],  we also observed that the Ki67 index was 
strongly correlated with the SUVmax.  This ﬁnding 
might indicate that the acceleration of glucose metabo-
lism supplies enough energy to exaggerate the meta-
bolic activity in aggressive tumors [14].  We also 
examined the correlation between SUVmax and Ki67 
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Fig. 1　 The receiver operator characteristic (ROC) curve for 
SUVmax in the diﬀerent level of Ki67 (high: ＞14%, low: ｦ14%) in 
Luminal type.  The curve describes the association between sensi-
tivity and speciﬁcity at diﬀerent thresholds.  The area under the 
curve (AUC) was 0.664 and the optimal cut-oﬀ level of SUVmax 
was 4.34.
in only the luminal cases.  Luminal-type tumors are 
classiﬁed as either Luminal A or Luminal B,  and this 
classiﬁcation inﬂuences the treatment decisions 
because there are diﬀerences in drug sensitivity 
between Luminal A and B patients [6].
　 Patients with ER positivity have been reported to 
show poor responses to chemotherapy [16,  17],  but 
neoadjuvant chemotherapy seems to be eﬀective for 
Luminal B patients by reducing their tumor volume 
[17].  Therefore,  as adjuvant postoperative therapy 
for Luminal B patients,  chemotherapy is recom-
mended in addition to hormone therapy,  and in some 
cases neoadjuvant chemotherapy is also recommended,  
whereas the standardized drug therapy for Luminal A 
is only adjuvant hormone therapy [6].  The Ki67 index 
can be used to help classify Luminal A and B cases:  
the cut-oﬀ point is 14ｵ [6].  Considering the possi-
bility of an indication for neoadjuvant chemotherapy,  
it is important to precisely diagnose Luminal A versus 
B pre-operatively.  This classiﬁcation can also be 
applied to the recurrence of breast cancer,  for which 
the optimal drug treatment must be chosen.
　 Niikura et al.  reported that the Ki67 labeling index 
varies according to the area of tissue selected in the 
evaluation [18].  We commonly evaluate preoperative 
Ki67 by using a core needle biopsy (CNB) specimen,  
but a CNB provides only a small quantity of specimen.  
We thus might not be able to evaluate Ki67 precisely 
using only a CNB specimen.  In the present study,  we 
created the ROC curve for Ki67 in ER-positive 
patients to assess whether the SUVmax can be used to 
diﬀerentiate the groups of high (＞14ｵ) and low 
(ｦ14ｵ) Ki67 patients.  The area under the ROC 
curve was 0.664,  which indicates low accuracy,  and 
thus the evaluation of SUVmax cannot supplant the 
Ki67 index,  but the evaluation of SUVmax may sup-
port the use of the Ki67 index and help identify the 
best treatment policy in luminal-type patients.  
Because the number of luminal-type patients in the 
present series was only 113,  there is room for the 
further consideration of this issue.
　 For the reason mentioned above,  we examined the 
correlation between SUVmax and Ki67 only in lumi-
nal-type patients.  Twenty-four of the 25 cases in the 
ER-negative group had high Ki67 values,  and there-
fore we judged that there was no need for the exami-
nation in the ER-positivity group.  The new classiﬁca-
tion of triple-negative breast cancer (TN) is very 
important to the decision-making process regarding the 
treatment strategy for TN [19].  It may also be useful 
to determine the SUVmax in ER-negative patients.
　 This study had some limitations.  The limited num-
ber of samples may have hampered the detection of 
slight but crucial signiﬁcant diﬀerences.  In addition,  
this was a retrospective study and it could have been 
inﬂuenced by biases associated with retrospective 
studies,  such as inherent selection bias.  The tumor 
grade,  Ki67 index,  and subtype of tumor are the 
major important predictive factors in breast cancer,  
and our present ﬁndings revealed that these factors 
are associated with 18F-FDG uptake.  An association 
between SUVmax and the prognosis of breast cancer 
may exist,  as was mentioned in previous reports [2,  
4],  but we were not able to examine this association 
because of the short follow-up period in this study.
　 In conclusion,  our results indicate that the 
SUVmax is associated with almost all of the commonly 
used clinicopathological characteristics in primary 
breast cancer.  18F-FDG PET/CT alone cannot replace 
the evaluation of Ki67,  but it has the potential to be 
useful by providing additional information about 
luminal-type cancer in the preoperative assessment of 
primary IDC.  More thorough investigations of larger 
cohorts with respect to the association between FDG 
uptake and prognosis might give more precise results.
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